ARB-202 is under clinical development by Arbele and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I drugs for Pancreatic Cancer have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ARB-202’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ARB-202 is under development for the treatment of refractory pancreatic cancer, refractory bile duct cancer (cholangiocarcinoma), stomach cancer, gastrointestinal tumor, liver, colorectal and colon cancer. It is a bi-specific monoclonal antibody acts by targeting CDH17/CD3 (cadherin-17/CD3).
Arbele is a biopharmaceutical company that discovers and develops immunotherapeutics for the treatment of cancers, immune disorders and neurological diseases. Arbele is headquartered in Hong Kong.
For a complete picture of ARB-202’s drug-specific PTSR and LoA scores, buy the report here.